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ABSTRACT 
Cancer is the second leading cause of disease death worldwide. Whereas 
cancer immunotherapy with cytokines in previous researches demonstrated effective 
in activating immune response against tumor cells, one major obstacle with the use 
of these cytokines is their severe side effects when delivered systemically at high 
doses. Another challenge is that tumor cells often lead to immune destruction by 
evading immunosurveillance of the innate immune system such as natural killer (NK) 
cells as well as of the Fas-mediated apoptosis by down-regulating their expression. 
In the present study, a novel fusion protein—IL-12/FasTI, consisting of mIL-12 and 
the transmembrane and intracellular domains of Fas, was successfully created. The 
fusion construct (pmIL-12/FasTI) in an expressing vector was transfected into the 
mouse pulmonary carcinoma cell line TC-1 and stable cell clones expressing the 
fusion protein were selected. In vitro studies confirmed the functions of the 
bifunctional protein as the induction of apoptosis of tumor cells and NK cell 
activation by increased IFN-γ production and cytotoxicity. This new approach may 
generate a promising therapeutic agent for tumor treatment when combined with tumor 
cell-specific gene delivery vehicles such as nanoparticles. 
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CHAPTER ONE 
A REVIEW OF INTERLEUKIN-12 AND FAS BASED ANTI-TUMOR 
IMMUNOGENE THERAPIES 
The Biology of Cancer 
Cancer is the second leading cause of disease death in the U.S and worldwide. 
Most recent statistics indicate that in 2014, there were an estimated 1,665,540 cancer 
cases diagnosed and 585,720 cancer deaths in the US. Up to now there are more than 100 
different types of cancer that have been identified, named specifically for the organ or 
type of cell in which they start.  
The past two decades have witnessed tremendous advances in our understanding 
of the pathogenesis of cancer. It is now clearly understood that cancer arises through a 
multi-step, mutagenic process with a plethora of underlying genetic causes to accomplish 
an unwarranted survival and proliferative advantage [K. Fernald, et al. 2013]. In the 
course of remarkable progress in cancer research, it has been proposed that six hallmarks 
of cancer together constitute an organizing principle that provides a logical framework 
for understanding the remarkable diversity of neoplastic diseases [D. Hanahan and R. 
Weinberg, et al. 2000]. They include sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis. Many of these phenotypic traits can be brought 
about by genomic instability that involve the gain-of-function mutation, amplification, 
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and/or overexpression of key oncogenes together with the loss-of-function mutation, 
deletion, and/or epigenetic silencing of key tumor suppressors [D. Hanahan and R. 
Weinberg, et al. 2002]. Conceptual progress in the last decade has added two emerging 
hallmarks of potential generality to this list—reprogramming of energy metabolism and 
evading immune destruction [D. Hanahan, et al. 2011].  
Figure1. Hallmarks of Cancer: the next generation (Hanahan D and Weinberg RD.2011) 
Cancer evolves through random mutations and epigenetic changes that alter these 
pathways followed by clonal selection of cells that can survive and proliferate under 
circumstances that would normally be deleterious. Although a number of oncogenes and 
tumor suppressor genes, such as p53 and Rb, are frequently mutated in cancer cells, there 
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also appears to be a large number of low-frequency changes that contribute to onco-
genesis. Indeed, data from tumor sequencing projects reveal an astounding diversity of 
mutations in tumors. In one study, Stratton and colleagues estimate that individual 
mutations in as many as 20% of all kinases can play an active role in tumori-genesis 
[Greenman et al. 2007]. Therefore, better understanding of the biology of cancer disease 
and improvements in treatment are greatly needed. Increasing evidence supports the 
concept that a rare and specialized population of cancer cells, so-called cancer stem cells 
(CSCs) (or cancer-initiating cells) with stem cell-like characteristics, is responsible for 
tumor growth, maintenance, and recurrence. CSCs also exhibit characteristics that render 
them resistant to both radiation and chemotherapy, and therefore they are believed to play 
a role in treatment failure. This has led to the hypothesis that traditional therapies that 
indiscriminately kill tumor cells will not be as effective as therapies that selectively target 
cancer-initiating cells [Morrison et al. 2013]. Furthermore, cancer is also an 
inflammatory disease. The relationships and mechanisms through which infection and 
inflammation increase cancer risk and promote tumor development were recently 
reviewed [Karin and Greten et al. 2005]. It is well established that chronic infections 
with hepatitis B and C viruses (HBV, HCV) represent major risk factors for development 
of hepatocellular carcinoma (HCC). While chronic H. pylori infection is the major risk 
factor for gastric cancer [Kuper et al., 2000]. It was proposed that in both cases and 
others the infectious agent leads to activation of NF-kB in myeloid cells (and eventually 
in lymphoid cells), resulting in production of growth and survival factors that stimulate 
tumor progression and development [Karin and Greten et al.  2005].  
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Cancer immune surveillance is considered to be an important host protection 
process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction 
of host and tumor cells, three essential phases have been proposed: elimination, 
equilibrium and escape [Dunn et al. 2002]. Nascent transformed cells can be eliminated 
initially and efficiently by immune effector cells such as NK cells and by the secreted 
IFN-γ in an innate immune response. The process of elimination includes innate and 
adaptive immune responses to tumor cells. Several effector cells such as NK, NKT and 
γδT cells are activated by the inflammatory cytokines, which are released by 
macrophages and stromal cells surrounding the tumor cells. The secreted cytokines 
recruit more immune cells, which produce other pro-inflammatory cytokines such as IL-
12 and IFN-γ. Fas ligand (FasL) and TRIAL-mediated killing of tumor cells by NK cells 
release tumor antigens which lead to adaptive immune responses [Smyth et al. 2000; 
Mori et al. 1997]. In the crosstalk between NK cells and Dendritic cells (DCs), NK cells 
promote the maturation of DCs and their migration to draining lymph nodes, resulting in 
the enhancement of antigen presentation to naïve T cells for clonal expansion of 
cytotoxic T cells (CTLs). The tumor antigen-specific T lymphocytes are recruited to the 
primary tumor site and directly attack and kill tumor cells with the production of 
cytotoxic IFN- γ [Zitvogel et al. 2006]. Elimination of transformed cells results in 
immune selection, which induces tumor variants that decrease immunogenicity and 
become resistant to immune effector cells in the equilibrium phase. These cells are more 
capable of surviving in an immunocompetent host. Eventually, when the tumor size can 
be detected by imaging diagnosis, tumor-derived soluble factors can induce several 
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mechanisms for escape from immune attack in the tumor microenvironment [Kim, et al. 
2006]. 
Any potential therapy to treat and possibly cure cancer must show differential 
toxicity toward tumor cells relative to normal cells. In principle, cancer can be treated by 
inducing cancer cells to undergo apoptosis, necrosis, senescence, or differentiation. These 
changes can be brought about by disrupting cancer cell-autonomous processes, by 
interfering with autocrine/paracrine signaling within tumors, or by blocking heterotypic 
signaling between tumor cells and the surrounding stromal tissue or blood vessels. 
Enhancing immune surveillance against cancer cells expressing novel antigens is also an 
attractive approach that has shown efficacy in specifically killing cancer cells [Muller 
and Scherle, et al. 2006]. The choice of cancer therapy depends upon the location and 
grade of the tumor and the stage of the disease, as well as the general state of the patient. 
This literature review will focus on the comparison of conventional and current strategies 
against different cancer types. 
Cancer Therapies 
Surgery is one of the most commonly performed traditional cancer treatment. 
Theoretically non-hematological cancers can be cured if entirely removed by surgery in 
the absence of tumor metastasis. When the cancer has metastasized to other sites in the 
body prior to surgery, complete surgical excision is usually impossible. In addition to 
removal of the primary tumor, surgery is often necessary for staging, e.g. determining the 
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extent of the disease and whether it has metastasized to regional lymph nodes. Staging is 
a major determinant of prognosis and of the need for adjuvant therapy.  
Chemotherapy is the treatment of cancer with one or more cytotoxic anti-
neoplastic drugs (chemotherapeutic agents) as part of a standardized regimen. Traditional 
chemotherapeutic agents act by killing cells that divide rapidly, one of the main 
properties of most cancer cells; hence, chemotherapy has the potential to harm healthy 
tissues, especially those tissues that have a high replacement rate such as normal cells in 
bone marrow and digestive tract and blood cells. Targeted therapy is a form of 
chemotherapy that can target specific molecular differences between cancer and normal 
cells, which act by blocking essential biochemical pathways or mutant proteins that are 
required for tumor cell growth and survival [Druker et al. 2003]. The first targeted 
therapy to be developed blocked the estrogen receptor molecule, inhibiting the growth of 
breast cancer. Another common example is the class of Bcr-Abl inhibitors, which are 
used to treat chronic myelogenous leukemia (CML) [“Targeted cancer therapy”. 2014]. 
Currently, there are targeted therapies for breast cancer, multiple myeloma, lymphoma, 
prostate cancer, melanoma and other cancers [Takimoto et al. 2008]. Dosage of 
chemotherapy can be difficult; if the dose is too low, it will be ineffective against the 
tumor, whereas, at excessive doses, the toxicity (side-effects) will be intolerable to the 
patient [Corrie et al. 2008]. In combination with surgery, chemotherapy has proven 
useful in a variety of different cancer types including breast cancer, colorectal cancer, 
pancreatic cancer, and certain lung cancers. The overall effectiveness of chemotherapy 
varies from being curative for some cancers such as leukemia [Nastoupil et al. 2012], to 
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being ineffective such as in some brain tumors because the blood–brain barrier poses a 
difficult obstacle to pass to deliver chemotherapy to the brain. [Rampling et al. 2004]. 
The effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. 
Radiation therapy involves the use of ionizing radiation in an attempt to either 
cure or improve the symptoms of cancer. The principle of radiation therapy is to damage 
the DNA of cancerous tissue leading to cellular death. To spare normal tissues such as 
skin or organs, which radiation must pass through to eliminate the tumor, shaped 
radiation beams are aimed from several angles of exposure to intersect at targeted tumor, 
providing a much larger absorbed dose than in the surrounding healthy tissues. The 
radiation is most commonly low energy X-ray beams for treating skin cancers, while 
higher energy X-ray beams are majorly used in the treatment within the body [Hill et al. 
2014]. As with chemotherapy, different types of cancers respond differently to radiation 
therapy. 
One major issue of these conventional cancer treatments including the 
combination of surgery and chemo-/radiation therapies is toxicity, especially when tumor 
metastasis occurs. Further, blood vessels in tumors, which are formed due to tumor 
angiogenesis, are very different from those in normal tissues. As a tumor metastasizes, 
tumor cells furthest away from the blood vessels become hypoxia. To counteract this new 
blood vessels are signaled to grow. Because the newly formed tumor vasculature is 
poorly formed and does not deliver an adequate blood supply to all areas of the tumor, 
this leads to issues with drug delivery by the circulatory system [Minchinton et al. 2006]. 
- 8 -
Resistance is another major cause of treatment failure in chemotherapeutic drugs. There 
are a few possible causes of drug resistance in cancer, one of primary reasons is anti-
tumor drug efflux caused by ATP-driven pumps [Chen et al. 2013]. It was demonstrated 
that cancer stem cells (CSCs) have an overexpression of ATP-binding cassette (ABC) 
transporters, which transport a wide variety of substrates including chemo-drugs from 
inside the cell to the outside.  
The past few decades have seen a groundswell of research on the immune system 
yielding a deeper understanding of how cancer progresses and offering new approaches 
to stop it. This progression has made the paradigm for cancer treatment to evolve from 
relatively non-specific cytotoxic agents to selective, mechanism-based therapeutics.  
Cancer immunotherapy is the use of immune system or its products to treat 
cancer. This strategy exploits the fact that cancer cells often have subtly different surface 
molecules that can be detected by the immune system. These molecules, known as tumor 
antigens, are most commonly proteins but also include molecules such as carbohydrates. 
Immunotherapies fall into three major groups: cellular, antibody and cytokine. Cellular 
therapies, also known as cancer vaccines, usually involve the removal of certain cancer 
cells or immune cells from cancer patients, modification with adjuvant materials to make 
complexes, and injection of the complexes back to patients. The purpose of cancer 
vaccines is to elicit a more powerful active immunity in the patient since any response of 
the patient’s own immune system to tumor cells-immunosurveillance-has clearly failed in 
cancer patients. Cancer vaccines include whole tumor cell vaccines, tumor-extracted 
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protein vaccines, tumor antigen vaccines, dendritic cell (DC)-mediated vaccines and 
tumor antigen-encoding virus vaccines. These vaccines can be delivered alone or with 
adjuvants [Pardoll et al. 1998; Jager et al. 2002; Schmitz et al. 2002; Lysaght et al. 
2003]. Cell types that can be used in this way are natural killer cells, lymphokine-
activated killer cells, cytotoxic T cells and dendritic cells. For instance, vaccination using 
dendritic/tumor cell hybrids represents a novel and promising cancer immunotherapy. 
[JinHua Li et al. 2007] Dendritic cells (DCs) are professional antigen-presenting cells 
and have been studied as an anti-tumor immune response activator in many ways, 
including tumor antigen pulsing, tumor antigen gene transfection and DC/tumor cell 
fusion. [Rosenblatt J, et al. 2005; Farkas A, et al. 2006] This pilot study demonstrated 
that dendritoma vaccines could be administered safely to patients with metastatic renal 
cell carcinoma, while producing both clinical and immunologic evidence of response. 
Production and use of vaccines in this protocol were approved and monitored by the Food 
and Drug Administration (IND 9519) 
Antibody therapies are the most successful immunotherapy, with approved 
treatments for a wide range of cancers. Antibodies are proteins produced by the immune 
system that bind to a target antigen on the cell surface. Antibodies are a key component 
of the adaptive immune response, playing a central role in both in the recognition of 
foreign antigens and the stimulation of an immune response to them. It is not surprising 
therefore, that many immunotherapeutic approaches involve the use of antibodies. The 
advantage of monoclonal antibody technology has made it possible to raise antibodies 
against specific antigens, such as the unusual antigens present on tumor surfaces. 
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Monoclonal antibody therapy uses monoclonal antibodies (mAb) to specifically bind to 
specific cells or proteins against malignant, so as to stimulate the patient’s immune 
system to attack cancer cells. Antibodies are also referred to as murine, chimeric, 
humanized and human. Murine antibodies were the first to be produced, which carry a 
great risk of immune reaction, because the antibodies are from a different species. 
Chimeric antibodies were the first attempt to reduce the immunogenicity of these 
antibodies. Chimeric antibodies are murine antibodies with a specific part of the antibody 
replaced with the corresponding human constant region. Humanized antibodies are 
almost completely human; only the complementarity determining regions of the variable 
regions are derived from murine antibodies. Human antibodies have completely human 
DNA [Harding FA, et al. 2010]. 
Cytokines are a broad group of proteins, which are released in response to diverse 
range of cellular stresses, including carcinogen-induced injury and inflammation. As the 
mixture of cytokines that is present in the tumor microenvironment shapes host immunity, 
therapeutic manipulation of the cytokine environment constitutes cytokine therapies to 
stimulate protective responses. The infusion of high doses of IL-2 mediates tumor 
regression in a minority of patients with renal-cell carcinoma (RCC) or melanoma. 
Although the toxicities of this approach ultimately proved limiting, it is noteworthy that 
some patients with disseminated disease achieved durable clinical benefits [Fyfe G et al. 
1995]. Systemic IL-12 elicits striking antitumor effects in mouse models, but clinical 
testing was abruptly curtailed due to unexpected severe toxicities [Atkins MB et al. 1997]. 
In addition, systemic GM-CSF confers some clinical advantages in melanoma, prostate 
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cancer and pulmonary metastases, perhaps through immune stimulation. [Anderson PM 
et al. 1999]  
Characteristics of Natural Killer Cells 
Natural killer (NK) cells are large granular bone marrow-derived lymphocytes 
serving as an important component of the innate immunity. They act as a ‘rapid force’ 
that attack transformed and/or tumor cells based on their ability to lyse tumor cells 
without prior immune sensitization [Trinchieri G et al. 1989; Moretta L et al. 2001; 
Ljunggren H.G et al.2007]. NK cells respond faster than T and B cells as they do not 
have to rearrange the T-cell receptor or the immunoglobulin genes to create a highly 
diverse repertoire of specificities. Instead, they recognize the target cells by employing 
‘missing-self recognition’. Furthermore, some genetic experiments in mice recently 
reveal that absence of NK cells results in spontaneous tumor development and induced 
primary oncogenesis [Hayakawa Y et al. 2006]. 
NK cell function is controlled by a balance of NK cell inhibitory and activating 
signals. Several inhibitory receptor families have been identified in mice and humans 
[Yokoyama WM et al. 1995; Wilson MJ et al. 2000] including killer inhibitory receptors 
(KIRs) and NKG2A [Ljunggren H.G et al.2007]. NK cell inhibitory receptors bind to 
self-MHC (major histocompatibility complex) class I molecules, and this binding results 
in profound inhibition of the NK cells [Raulet DH et al. 2001]. A wide variety of NK 
cell-activating receptors have also been found. In humans, major NK activating receptors 
include NKp30, NKp44 and NKp46 (collectively called natural cytotoxic receptors 
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NCRs), NKp80, NKG2D, CD2 and DNAM-1. Spontaneous cytotoxic activity is mainly 
triggered by NKG2D, leukocyte adhesion molecule DNAX accessory molecule1 
(DNAM-1), and natural cytotoxicity receptors. Specifically, NK cells use their activating 
receptors like NKG2D to recognize stress induced ligands on abnormal cells such as 
tumor cells. Human NKG2D ligands include MHC class I chain-related protein (MICA), 
MICB, ULBP and RAET1 [Bauer S et al. 1999]. Mouse NKG2D ligands include retinoic 
acid early transcript 1(Rae1), histocompatibility 60 (h60) and mouse UL16-binding 
protein-like transcript (MULT1). Many tumor cell lines and primary tumors from diverse 
tissue origins express NKG2D ligands. For instance, many primary tumor isolates from 
carcinoma (lung, breast, kidney, prostate, ovary and colon), melanoma and some primary 
leukemia cells express MICA. About 75% of primary cutaneous melanoma isolates and 
50% of metastatic melanoma lesions express MICA protein [Vetter CS et al. 2002]. It 
was hypothesized that oncogenes and tumor suppressor genes involved in the process of 
transformation regulate NKG2D ligand expression. In addition, because these ligands are 
not widely expressed on healthy adult tissue, NKG2D ligands may present a useful target 
for immunotherapeutic approaches in cancer. Novel therapies targeting NKG2D ligands 
for the treatment of cancer have shown pre-clinical success and are poised to enter into 
clinical trials. [Diefenbach et al. 2001] 
A balance in signaling mediated by activating and inhibitory receptors tightly 
regulates NK cell function. Thus, loss or down-regulation of MHC class I can render cells 
susceptible to NK cell-mediated lysis when an activating ligand is engaged [Moretta L et 
al. 2001]. More in general, in addition to loss or down-regulation of MHC class I, NK 
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cell can be activated by various other stimuli, such as contact with dendritic cells(DC), 
binding of IgG immunocomplexes, direct engagement of NKR by stress-induced tumor-
associated molecules or pathogen-derived products, and several cytokines such as IL-1, 
IL-2, IL-12, IL-15, IL-18, IL-21 and type I interferons (IFNs). Upon cytokine stimulation, 
NK cells become lymphokine-activated killer (LAK) cells that proliferate, produce 
cytokines such as IFN-γ, and up-regulate effector molecules such as adhesion molecules, 
NKp44, perforin, granzymes, Fas ligand (FasL), and TRAIL [Trinchieri G et al. 1989, 
2003; Bottino CL et al. 2004; Moretta et al. 2004; Medvedev AE, et al. 1997; Johnsen 
AC et al. 1999; Mirandola PC et al. 2004]. Essentially the NK cell lineage has been 
considered for cancer eradication owing to its ability to kill a wide variety of tumor cells 
spontaneously while sparing normal cells, which takes place as: secretion of cytotoxic 
IFN- γ, perforin/granzyme-dependent necrosis of target cells and induced apoptosis of 
target cells through Fas/FasL or TRAIL signaling pathway [Smyth MJ, et al. 1999]. 
Early 1980s clinical trials started introducing IL-2 activated NK cells in the 
treatment of heavily tumor-burdened patients with solid primary or metastasized cancers. 
Subcutaneous injection of NK-stimulating doses of IL-2 showed 15-30% positive effect 
in patients with advanced RCC or melanoma [Rosenberg SA et al. 1993]. However, both 
RCC and melanoma patients showed a variable susceptibility to apoptosis induced by 
TNF ligand members. Also and unfortunately, IL-2 treatment is associated with life-
threatening toxicity, essentially represented by capillary leak syndrome [Fehniger TA et 
al. 2002]. Another limitation of this approach is the fact that IL-2 but not IL-15 activated 
NK cells increase their sensitivity to apoptosis when in contact with vascular endothelium, 
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likely causing a decrease in NK cell migration toward the cancer area. IL-15 appears as 
more efficient than IL-2 in expanding the NK cell compartment because it promotes the 
survival of NK cells and protects NK cells from AICD [Waldmann TA et al. 2001]. Thus 
more recently, strategies favoring IL-15 trans-presentation to NK cells have been 
proposed; alternatively, early-acting cytokines such as Flt3-L, SCF, and IL-7 can be used 
to enhance NK cell numbers.  
Differently from IL-2 and IL-15, IL-12 can increase NK-cell mediated IFN- γ 
production by binding to IL-12 receptor (IL-12R), and IL-1 and IL-18 potentiate the 
effect of IL-12 by up-regulating the IL-12Rs expression on NK cell surface. A substantial 
amount of evidence has demonstrated a critical role for endogenously produced IFN-γ in 
promoting host responses to primary and transplanted tumors. IFN-γ exerts its effects on 
cells by interacting with a distinct high affinity receptor that is expressed on virtually all 
normal cell surfaces. IFN-γ has been shown to suppress tumor angiogenesis, and to 
induce TRAIL-/FasL-mediated cellular susceptibility to apoptosis in a variety of tumor 
cells [Smyth MJ et al. 2003; Cretney E et al. 2002]. In addition, IFN-γ is also a major 
macrophage-activating factor capable of inducing in macrophages the capacity to non-
specifically kill a variety of tumor targets [Schreiber RD et al. 1986; MacMicking J, et al 
1997]. More recent experiments further demonstrate that endogenously produced IFN-γ 
participates in preventing primary tumor development by acting on both the innate and 
adaptive immune responses against tumors [Street SE et al. 2001]. In one experiment, 
MCA-induced sarcomas from IFN-γ insensitive mice that lack IFNGR1 chain were 
engineered for enhanced expression of two IFN-γ-inducible components of MHC class I 
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processing and presentation pathway to evaluate whether IFN-γ functioned. The result of 
this study showed that enforced expression of syngeneic TAP1 in IFN- γ-insensitive 
sarcoma cells converted the aggressively growing tumors into ones that were rejected in 
naïve syngeneic mice, which defined one important IFN- γ-induced response in tumors 
that promotes tumor rejection.  Moreover, the IFN- γ-dependent enhancement of tumor 
immunogenicity not only serve as a mechanism for increased host protection against 
tumor development, but may also induce type I immunity and counteract tumor escape 
mechanisms that are actively promoted by advanced cancer cells and regulatory T 
lymphocytes through the secretion of type II cytokines such as IL-10 and TGF-β. To this 
regard, IL-21 proves promising in the context of anti-tumor immunotherapy [Davis MR 
et al. 2015]. IL-21, which can lead to an augmentation of NK effects, has been found to 
promote both the expression of genes associated with type I response and the terminal 
differentiation of the highly cytotoxic CD16+ NK cell subset, thus potentially directing 
ADCC against tumor cells. 
More advanced tumor cells are able to evade immunosurveillance by elements of 
the innate immune system such as NK cells, by down-regulating or “shedding” certain 
NKG2D ligands like MULT1. Moreover, they also can avoid certain apoptosis pathway 
such as Fas/FasL by down-regulating its expression. Recent studies reported the design of 
anti-tumor activity of novel fusion protein approaches. One fusion protein is 
MULT1E/FasTI, which consists of extracellular domain of MULT1 and the 
transmembrane and intracellular domain of Fas. The fusion construct was transfected into 
the mouse pulmonary carcinoma cell line TC-1. In vitro cell culture studies demonstrated 
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that the binding of NKG2D/Fc to MULT1E/FasTI expressed on tumor cells was able to 
elicit apoptosis and to activate NKG2D-expressing cells including NK cells. In vivo 
subcutaneous tumor studies demonstrated that tumor cells-expressing MULT1E/FasTI 
grew significantly slower than cells without the fusion protein. Pulmonary metastasis 
studies showed that most of the mice completely rejected tumor cells expressing 
MULT1E/FasTI [HSR K, et al. 2010]. Another example of effective fusion protein is 
MULT1/mIL-12, which conjugated MULT1 (NKG2D ligand) with murine IL-12. 
Resulting fusion protein was transfected into TC-1 cell line. RT-PCR and fluorescent 
microscopy result showed a significant level of MULT1/mIL-12 secretion, NK cell 
activation and IFN-γ production and cytotoxicity within tumor cell micro-environment. 
[Ashlee H. Tietje, et al. 2013]. The results demonstrate that the fusion protein treatment 
with engagement of NK cells and other immune cells can activate NK cells through 
NKG2D receptor or IL-12 receptor to directly lyse the tumor cells and exert bi-functional 
against tumor cells.  
Immunology of Interleukin-12 
Interleukin-12 (IL-12), known as NK cell stimulatory factor 2, is an activator and 
initiator of NK cell proliferation [Robertson, et al. 1992; Rudolfo M, et al. 1999]. It was 
identified as a heterodimeric cytokine composed of two covalently linked p35 and p40 
[Kobayashi M et al. 1989]. IL-12 binds to the IL-12 receptor, which is a heterodimeric 
receptor formed by IL-12R-β1 and IL-12R-β2. Upon binding, IL-12R-β2 becomes 
tyrosine phosphorylated and provides binding sites for kinases, Tyk2 and Jak2 [Wang KS 
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et al. 2000]. These are important in activating critical transcription factor proteins such as 
STAT4 that are implicated in IL-12 signaling in T cells and NK cells. Initial 
characterization of its biological activities revealed that IL-12, when added to human 
peripheral blood lymphocytes, induced IFN-γ production, increased NK cell cytotoxicity 
as well as T cell proliferation in response to mitogenic lectins and phorbol diesters. 
Subsequent studies indicated that IL-12 could boost the generation of cytotoxic T cells by 
promoting the transcription of genes encoding cytolytic factors including perforin and 
granzymes [Trinchieri G et al. 2003]. 
A number of biological properties of human IL-12 have been evaluated in vitro. 
Among its properties are the ability to act as a NK cell and T cell growth factor, to 
enhance NK/LAK cell cytolytic activity, to augment cytolytic T cell responses and to 
induce secretion of cytokines, particularly IFN-γ, from NK and T cells [Kobayashi M et 
al. 1989; Gately et al. 1991; Robertson MJ et al.1992; Brunda MJ et al. 1993]. Since 
both T and NK cells have been implicated as antitumor effector cells and IFN-γ has been 
shown to have antitumor activity, IL-12 was believed potential to be used as an 
immunomodulatory cytokine in the therapy of malignancies. More recent studies 
demonstrated that the heterodimeric cytokine IL-12 is a key mediator of both innate and 
cellular immunity with potent anti-tumor and anti-metastatic activity by majorly 
interacting with its receptor. [Brunda MJ et al. 1993; Tsung K et al. 1997; Rodolfo M et 
al. 1999]. IL-12 also contributes to activation of CD8+ T cells in absence of T cells and 
NK cells. (These antitumor and anti-metastatic activities of IL-12 have been extensively 
shown in murine models including melanomas, mammary carcinoma, colon carcinoma, 
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renal carcinoma and sarcomas [Colombo MP et al. 2002]. Recombinant IL-12 given 
systemically had powerful antitumor activities in murine models that led to its clinical 
development, which began in 1994.  In preclinical models of cancer, the activity of IL-12 
has been investigated in patients with advanced solid tumors and hematologic 
malignancies, as either monotherapy or in combination with other treatment. In Phase I 
clinical trials designed in an intrapatient dose escalation fashion, it was not realized that 
initial low doses of IL-12 resulted in desensitization against the biological effects of IFN-
γ produced upon subsequent IL-12 doses. Intravenous (i.v.) doses, which were tolerated 
in Phase I, caused severe toxicity in Phase II clinical trials as many other cytokines and 
thus put a stop to the clinical development of this active antitumor agent for several years. 
Targeted delivery of IL-12 to the tumor environment or gene transduction of malignant 
cells with IL-12 genes is expected to increase the therapeutic index of the cytokine. 
Efforts have been given to generate local high dose of IL-12 therapy. In one study, local 
high doses of IL-12 were achieved by a glycosylphosphatidylinositol (GPI)-anchoring 
technology. GPI-anchored IL-12 was successfully expressed on the cell surface as 
indicated by FACS analysis and IL-12 ELISA assay, which enhanced lymphocyte 
infiltration and significantly inhibited tumor growth. More importantly, when GPI-
anchored IL-12 and GPI-anchored IL-2 were co-delivered, a synergistic anti-tumor effect 
was observed in both subcutaneous and intravenous tumor models [Jianfei Ji et al. 2004]. 
Gene encoding lymphocyte attracting chemokines can be successfully combined with IL-
12 therapy. This approach has shown remarkable efficacy with adenoviruses encoding the 
chemokines lymphotactin and IP-10 [Emtage PC et al. 1999]. Therefore, a general 
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mechanism of action for synergistic combinations has been proposed in which a halt in 
tumor growth by angiogenesis inhibition and NK activation trailblaze the route for 
artificially boosted T cell responses. Gene transfer of IL-12 into tumors is now entering 
clinical testing and it is hoped that the safety records will be as good as the preclinical 
data.  
Fas Mediated Apoptosis Pathway 
Fas receptor (Fas), also known as apoptosis antigen 1 (APO-1), cluster of 
differentiation 95 (CD95), is a transmembrane cell-surface death receptor that belongs to 
the tumor necrosis factor (TNF) receptor superfamily. Fas contains three cysteine-rich 
extracellular domains at the N-terminus, which are responsible for ligand binding, the 
transmembrane domain, and an intracellular death domain (DD) of about 80 amino acids 
that is essential for transducing the apoptotic signals [Peter ME et al. 2003]. Binding of 
Fas ligand (FasL or CD95L) to Fas receptor results in aggregation of the receptor 
molecules and recruitment of the adapter molecule, Fas-associated death domain (FADD), 
through DD-DD interactions. Fas forms the death-inducing signaling complex (DISC) 
upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent 
cell causes oligomerization of Fas. Recent studies which suggested the trimerization of 
Fas could not be validated. Other models suggested the oligomerization up to 5-7 Fas 
molecules in the DISC [Wang et al. 2010]. FADD also contains a death-effector domain 
(DED), which facilitates binding to the DED of FADD-like interleukin-1 beta-converting 
enzyme (FLICE), more commonly referred to as caspase-8. Active caspase-8 is then 
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released from DISC into the cytosol, where it cleaves effector caspases such as caspase-3 
that in turn cleave a restricted set of target proteins and are responsible for apoptosis in 
the cell [Houston A et al. 2004]. 
Fas ligand is predominantly expressed in activated T lymphocytes and natural 
killer cells [Nagata S. et al 1997]. Likely, the most established proapoptotic activity of 
Fas is to mediate the apoptotic death of either virus-infected or cancer cells when 
engaged by a CD8+ cytotoxic lymphocyte (CTL).  In addition to the perforin/granzyme 
pathway and some indirect mechanisms involving cytokines such as tumor necrosis 
factor α (TNF α) and IFN-γ, Fas/FasL is a direct major system that both CTL as well as 
CD4+ cytolytic effector T cells use to eliminate neoplastically transformed cells [Lowin 
B, et al. 1994; Rouvier E et al. 1993; Stalder T et al. 1994]. Tumor cells have developed 
many strategies for escaping immune surveillance. One of these strategies is that tumor 
cells can escape from Fas-mediated apoptosis by decreasing surface expression of Fas 
[Moller P et al. 1994; Ivanov VN et al. 2003]. The CD95 apoptotic signal can also be 
inhibited at the level of the DISC via increased expression of cFLIP (cellular FLICE 
inhibitory protein), which can inhibit the interactions of caspase-8 and -10 with the DISC 
[Irmler M et al. 1997], or via reduced expression of FADD [Tourneur L et al. 2003] or 
caspase-8 [Teitz T et al. 2000]. Loss of apoptosis signaling through CD95 can also be the 
consequence of deregulation of the expression of the Bcl-2 family members [Igney FH et 
al. 2002], and downregulation and mutating pro-apoptotic genes such as BAX, APAF1 or 
Fas [Teitz T et al. 2000], thereby favoring tumor survival.  
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Apoptosis induction is the most well-established activity of CD95, documented 
and summarized in numerous articles. In the context of cancer, it is relevant that CD95L 
is one of only a few molecules that immune cells use to activate apoptosis pathways to 
eliminate cancer cells [Strasser A et al. 2009]. Apoptosis induction as a cancer cell 
killing strategy is presumed to be accomplished by tumor-infiltrating lymphocytes 
expressing CD95L. Apoptosis induction in cancer cells through CD95 is the only 
scenario in which recombinant CD95L could be used for cancer therapy. However, given 
the fact that almost all established cancers express CD95 and most cancer cells are 
resistant to apoptosis induction, stimulating CD95 on cancer cells may not be an effective 
approach to killing cancer cells. In addition, stimulation of CD95 could never be used 
therapeutically because of major side effects such as massive apoptosis induction in the 
liver [Ogasawara J et al. 1993]. In one present study, researchers intended to combine 
the NK cell-mediated cytolysis and Fas-mediated apoptosis into one fusion protein by 
using the extracellular domain of MULT1 and the transmembrane and intracellular 
domains of Fas in a mouse model. The engagement of NK cells and/or other immune 
cells with tumor cells expressing the fusion protein succeeded in not only sending an 
apoptotic signal to the tumor cells via Fas-induced mechanisms but also lysing directly 
by the activated NK cells. In this case, it is hypothesized that binding of MULT1 to 
NKG2D could contribute to the trimerization of Fas, although it has not been confirmed. 
The results demonstrated that this fusion protein exerted bi-functional anti-tumor effects 
in vitro and in vivo [Kotturi HSR et al. 2008].  
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In 2004, it was reported that stimulation of CD95 on 22 apoptosis-resistant cancer 
cell lines increase their motility and invasiveness in vitro [Barnhart BC et al. 2004].  It 
was demonstrated in various cancer cell lines that CD-95 mediated invasiveness requires 
activation of NF-κB and ERK, and involves active caspase-8 and urokinase plasminogen 
activator [Barnhart BC et al. 2004]. It is now widely accepted that once cancer cells 
acquire resistance to CD95-mediated apoptosis, further stimulation of CD95 is 
tumorigenic [Lee JK et al. 2003; Kleber S et al. 2008; Nijkamp MW et al. 2010]. 
Following up on the findings that CD95 contributes to the proliferation of cancer cells, it 
was also reported that the elimination of either CD95 or CD95L kills cancers (in vitro 
and in vivo) in a  process termed as DICE (death induced by CD95 or CD95L elimination) 
[Hadji A et al. 2014]. The activity of CD95 as a survival factor seems to be mostly 
relevant to cancer cells, as none of the normal tissues during embryonic development in 
either CD95 or CD95L knockout mice showed a growth defect. Consistently, it was 
demonstrated that blockade of Fas signaling in breast cancer cells suppressed tumor 
growth and metastasis [Q Liu et al. 2013]. In addition, in two ovarian cancer mouse 
models and one mouse model of chemically induced liver cancer, tumor formation was 
severely reduced in the absence of CD95 [Chen L et al. 2010; Hadji A et al. 2014].   
In conclusion, it is clear that up-regulation of wild-type Fas on the surface cells 
can result in programmed cell death by the Fas/FasL pathway. Given the fact that tumor 
cells may have exploited the presence of FasL on their cell surface to evade deletion by 
Fas-bearing tumor-specific cytotoxic T cells, enhanced Fas expression in cells which can 
be induced by cytotoxic drugs or via gene therapy is currently in therapeutic use.  
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Fusion Protein Based Bi-functional anti-tumor effects 
Fusion proteins or chimeric proteins (literally, made of parts from different 
sources) are proteins created through the joining of two or more genes that originally 
coded for separate proteins. Translation of this fusion gene results in a single or multiple 
polypeptides with functional properties derived from each of the original proteins. 
Recombinant fusion proteins are created artificially by recombinant DNA technology for 
use in biological research. A recombinant fusion protein is created through genetic 
engineering of a fusion gene. This typically involves removing the stop codon from a 
cDNA sequence coding for the first protein, then appending the cDNA sequence of the 
second protein in frame through ligation or overlap extension PCR. A linker sequence 
between two entities is often added, which makes it more likely that both proteins fold 
more independently and behave different biological functions as expected. The purpose 
of creating fusion proteins in drug development is to impart properties from each of the 
“parent” proteins to the resulting chimeric protein. Several chimeric protein drugs are 
currently available for medical use. 
Most cytokines act as soluble factors that bind and activate receptors on target 
cells [H. Schooltink et al.2002; J Vilcek et al. 2004].  Consequently, therapeutic use of 
cytokines for cancer therapy, for example by intravenous applications, requires that the 
cytokines reach the tumor and accumulate there in order to execute their immune-
modulating or cytotoxic activities. Importantly, delivery of the cytokines into the vicinity 
of the tumor cells in most cases should be sufficient for the induction of a stimulatory 
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activity on immune cells. Therefore, various cytokines have been approved for therapy of 
cancer and other diseases and many more are under development in the past years [E 
Ortiz-Sánchez et al. 2008]. 
IL-2 fusion proteins 
IL-2 is a pleiotropic and potent stimulator of the immune system including the 
activation of natural killer (NK) cells, monocytes and cytotoxic T cells. IL-2 can act 
directly by inducing apoptosis of tumor cells, but also indirectly by activation of 
cytotoxic cells, e.g. CTLs, NK cells, and macrophages, including the upregulation of 
MHC class II molecules [TR Malek et al. 2010]. IL-2 has been studied extensively since 
almost two decades for the generation of antibody-cytokine fusion proteins against cancer 
progression. From clinical trials, toxicity, especially vascular leakage syndrome, 
associated with therapeutic doses as well as a short serum half-life were identified as the 
two major problems that limit the therapeutic use of IL-2 [ET Harvill et al. 1995]. These 
issues demonstrated that a target-dependent accumulation of IL-2 and local immune 
response and improved pharmacokinetics is required. For example, IL-2 was used to 
generate an F(ab’)-IL-2 fusion protein directed against carcinoma cells [HP Fell et al. 
1991]. In a variety of fusion proteins, the cytokine was fused to C-terminus of the 
antibody heavy chain. Various IgG-IL-2 fusion proteins based on either IgG1 or IgG3 
established that these proteins exhibit a combination of biological properties including 
binding to tumor cells, Fc-mediated effector functions and stimulation of IL-2R 
expressing lymphocytes [ET Harvill et al. 1995, 1996; SD Gillies et al. 1992]. In further 
studies, cooperative activity of IL-2 with other cytokines was demonstrated by a 
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combination of anti-CD30, single-chain-Fv-Fc-IL-2 (scFv-Fc-IL-2) and scFv-Fc-IL-12 
fusion proteins, which resulted in enhanced activation of resting NK cells and tumor cell 
lysis [C Heuser et al. 2004; A Hombach et al. 2005].  
IL-12 fusion proteins 
IL-12 is a pro-inflammatory cytokine which induces proliferation of NK and T 
cells, production of other cytokines, e.g. IFN-γ and activation of effector T cells. 
Therefore, IL-12 has a central role in the induction of type I cell-mediated immune 
response in cancer and inflammation [M Xu et al. 2010]. Based on studies with IL-2 
fused to an antibody heavy chain, a similar fusion protein was generated utilizing IL-12 
[SD Gillies et al. 1992]. Because IL-12 is a heterodimer, the production of the IgG-IL-12 
fusion protein involved co-expression of the antibody light chain together with the p40 
unit, and the p35 unit fused to the C-terminus of the heavy chain. ScIL-12 was used to 
generate a variety of different antibody-IL12 fusion proteins, e.g. by fusing mouse scIL-
12 to the N-terminus of an anti-HER2 IgG3 heavy chain antibody, and antitumor activity 
was observed in syngeneic models of HER2-transfected CT26 tumor cells [LS Peng et al. 
1999]. When combining the anti-CD30 scFv-Fc-scIL-12 fusion protein with an anti-
CD30 scFv-Fc-IL-2 fusion protein, a cooperative activation of resting NK cells, induction 
of IFN-γ secretion and enhanced target cell lysis was observed in vitro [A Hombach et al. 
2005].  
In other cases, cytotoxic fusion proteins for tumor therapy are composed of an 
antibody -based targeting moiety and an effector molecule. Effectors may possess 
enzymatic activity conferring cytotoxicity after internalization or be an antibody-targeted 
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death-receptor ligand that induces apoptosis after interaction with a death receptor (DR). 
Fusion proteins makes use of cell-death inducing ligands such as tumor-necrosis factor, 
tumor necrosis factor α-related, apoptosis-inducing ligand Fas ligand and a tumor-
targeting antibody moiety. Cytotoxic fusion proteins based on caspase 6 have been 
explored. Expression of activated caspases in tumor cells would bypass situations in 
which the caspase activation process is inhibited by anti-apoptotic proteins such as 
inhibitors of apoptosis (IAPs) [CS Straub et al. 2011]. Death receptors (DRs) are 
members of the TNF-receptor (TNFR) superfamily with functions in regulation of 
survival and cell death, differentiation and immunity. Up to now a total of 18 ligands and 
28 receptors have been identified including TRAIL and Fas (CD95), and almost all of the 
receptors and ligands are transmembrane proteins [A Ashkenazi et al. 2002]. DRs are 
expressed on many types of tumors and this finding can be exploited to induce regression 
of tumors by treatment with their cognate ligands. After receptor ligand interaction, a 
death-inducing signaling complex (DISC) is assembled through the adapter protein FAS-
associated death domain (FADD), leading to recruitment and activation of caspase 8 
and/or caspase 10 [S Potala et al. 2008]. DRs can be engaged with recombinant 
trimerized ligand (TRAIL, TNF, and FASL) or with agonistic antibodies binding to the 
extracellular domain of the receptors with and without the requirement for cross-linking 
of the receptors [MA Lindsay et al. 2002]. 
Based on the overview above, It  can be  concluded that (i) cancer is a leading 
cause of death worldwide with capability to accumulate mutation and escape 
immunological killing; (ii) NK cells play a significant role in controlling tumorigenesis 
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mainly through cytotoxic killing of tumor cells; (iii) delivery of IL-12 will activate NK 
cells, reshape the tumor environment and induce tumor elimination; (iv) Fas is one of 
most important death receptors which can induce Fas/FasL-mediated apoptosis pathway 
and kill targeted cells; (v) the strategy of chimeric fusion proteins demonstrate more 
effective and promising in various diseases including cancer via a combination of 
different functional components.  
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CHAPTER TWO 
AIMS OF THIS STUDY 
As the first phase of the project, a fusion gene encoding mouse IL-12 and FasTI 
will be constructed and transfected to mouse lung carcinoma cell line TC-1. After the 
establishment of stable clones, the expression and the biological function of the fusion 
gene will be investigated in vitro with RT-PCR, qPCR, antibody staining, IFN-gamma 
production, cytotoxicity, and apoptosis. The specific aims of this study include: 
1. The construction of an expression vector containing the mIL12/FasTI 
fusion gene 
To avoid systemic toxicity of traditional IL-12 treatment and to realize the high 
concentration of IL-12 in the tumor environment, our mIL-12 control plasmid will 
include the cDNAs of mIL-12 as well as an anchoring sequence so that mIL-12 protein 
can be anchored on the cell surface once expressed successfully. Furthermore, Fas 
transmembrane and intracellular domain (FasTI) will be conjugated to mIL-12 to create 
the fusion gene mIL-12/FasTI, which is hypothesized to exert bi-functional anti-tumor 
elimination by both NK cell cytotoxicity and Fas-mediated apoptosis.  The cDNAs of 
mIL-12 and the transmembrane/intracellular domains of Fas will be cloned into 
expression vector pcDNA3.1/zeo (+). Meanwhile, a control vector containing cDNA of 
mIL-12 and cell membrane anchoring sequence will be produced.  
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2. Transfection and selection of stable clones expressing the 
mIL12/FasTI fusion protein 
To quickly evaluate if the fusion gene construct is correct at both protein and 
RNA levels, the resulting plasmid will first be used to transfect TC-1 mouse lung 
carcinoma cells using Lipofectamine2000. Stable clones will be selected and the 
expression of the fusion gene product will be confirmed at RNA level by RT-PCR, qRT-
PCR and protein level by immunohistochemistry. 
3. In vitro biological functions of the mIL12/FasTI fusion protein 
To determine if the fusion protein clones are able to exert anti-tumor functions 
effectively, two major parts of in vitro assays will be performed: the activation of NK 
cells and tumor cell apoptosis.  To detect if NK cells will be activated, the production of 
IFN-γwill be detected by using human IFN-γ ELISA assay kit.  The cytotoxicity of 
NK cells will be performed by MTS cell proliferation assay.  
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        CHAPTER THREE 
MOUSE INTERLEUKIN-12/FASTI: 
A NOVEL BI-FUNCTIONAL FUSION PROTEIN FOR 
CANCER IMMUNEGENE THERAPY 
 
Abstract 
Whereas cancer immunotherapy with cytokines in recent researches demonstrated 
effective in activating immune response against tumor cells, one major obstacle with the 
use of these cytokines is their severe side effects when delivered systemically at high 
doses. Another challenge is that advanced tumor cells often evade immunosurveillance of 
the immune system such as natural killer (NK) cells, cytotoxic T cells, as well as of the 
Fas-mediated apoptosis by down-regulating its expression. In the present study, we report 
the design and preliminary evaluation of the antitumor activity of a novel fusion 
protein—mIL-12/FasTI, consisting of mIL-12 and the transmembrane and intracellular 
domains of Fas. The fusion construct (pmIL-12/FasTI) was transfected into mouse lung 
carcinoma cell line TC-1. Stable cell clones expressing the fusion protein were 
established as assayed by RT-PCR and immunohistochemistry. ELISA and cell 
proliferation analyses demonstrated that NK cells were successfully activated by the 
fusion protein with increased IFN-γ production and cytotoxicity. Enhanced caspase 3 
activity of the clones when co-cultured with NK cells demonstrated that apoptosis was 
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induced through Fas/FasL signaling pathway.  The preliminary results confirmed the 
expected bi-functional fusion protein’s biological function. It represents a promising 
therapeutic agent for cancer treatment when combined with tumor cell-specific gene 
delivery vehicles such as Nano particles. 
Keywords: IL-12; Fas; NK cell; apoptosis 
Introduction 
 
Natural killer (NK) cells are an important part of the innate immune system that 
provide rapid responses to malignantly transformed or infected cells through 
immunosurveilance [E. Vivier, et al. 2011]. NK cells also help to shape the adaptive 
immunity by interacting with dendritic cells and producing the key cytokine IFN-γ. The 
NK cell lineage has been considered for cancer eradication owing to its ability to kill a 
wide variety of tumor cells spontaneously while sparing normal cells [M.J. Smyth, et al. 
2002]. Importantly, NK cells recognize potential target cells without the need for 
immunization or pre-activation compared with T cells. NK cells are regulated by the 
integration of signals triggered by ligands binding to different activating and inhibitory 
surface receptors. The activating receptors of human NK cells initiate cytolytic activity 
against virus-infected cells and malignantly transformed cells. Advanced tumor cells, on 
the other hand, are able to inhibit NK cells in a tumor microenvironment, where the 
cytokine profile favors tumor growth. One of the challenges ahead of cancer 
immunologists is how to reshape the tumor microenvironment to favor killer cells, such 
as NK cells, CTLs, γδT cells, etc. 
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Interleukin12 (IL-12), also known as NK cell stimulatory factor 2, is an activator 
and initiator of NK cell activation [Robertson, et al. 1992; Rudolfo M, et al. 1999]. One 
of IL-12’s major functions is to enhance NK cell-mediated IFN-γ production, which 
promotes host responses against tumors and regulates tumor development by interacting 
with its receptor. IL-12 also contributes to activation of CD8+ T cells in absence of 
helper T cells and NK cells. IL-12 has, therefore, been selected as a good candidate for 
cancer cytokine therapies. In experimental tumor models, recombinant IL-12 treatment 
has a dramatic anti-tumor effect on transplantable tumors, chemically induced tumors, 
and in tumors arising spontaneously in genetically modified mice. IL-12 utilizes effector 
mechanisms of both innate and adaptive immunities to mediate anti-tumor effects. IFN-γ 
and a cascade of other secondary and tertiary pro-inflammatory cytokines induced by IL-
12 have a direct toxic effect on the tumor cells or may activate potent anti-angiogenic 
mechanisms. [Mario P Colombo, et al. 2002] However, IL-12’s systemic high toxicity 
hindered its clinical applications [Atkins MB, et al. 1997; Car BD, et al. 1999]. Efforts 
have been given to generate local high dose of IL-12 therapy. For example, our lab 
successfully extended the GPI (glycosylphosphatidylinositol) anchor technology to 
murine IL-12. A fusion gene consisting of murine IL-12 cDNA and a GPI-anchoring 
signal from decay accelerating factor (DAF) was constructed. When transfected into 
B16F0 tumor cells the fusion gene expressed IL-12 on the cell surface in the GPI-
anchored form. ELISA assay and tumor infiltrated lymphocyte (TIL) analysis indicated 
that the GPI-anchored IL-12 is not only functional, but also showed significant 
synergistic anti-tumor effect when co-expressed with GPI-anchored IL-2. [Jianfei Ji, et al. 
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2002; Jianfei Ji, et al. 2004] Our lab also attempted to conjugate MULT1 (NKG2D 
ligand) with murine IL-12 to generate another anti-cancer fusion protein.TC-1 cells 
expressing the fusion protein effectively activated NK cells. [Ashlee H. Tietje, et al. 2014] 
When attached to mouse sonic hedgehog C-terminal domain, IL-12reduced dependency 
on IL-2 for NK cell proliferation. Intravenous injection of NK cells expressing this fusion 
protein significantly prolonged the survival time for tumor bearing mice [Zhu, et al. 
2012]. 
Fas (CD95) is a transmembrane cell surface death receptor that belongs to the 
tumor necrosis factor (TNF) receptor superfamily. Fas contains three cysteine-rich 
extracellular domains at the N-terminus, which are responsible for ligand binding, the 
transmembrane domain, and an intracellular death domain that is essential for transducing 
apoptotic signals [Peter Me, et al. 2003]. Binding of Fas ligand to Fas receptor results in 
the recruitment of Fas-associated death domain (FADD) through DD-DD interactions. 
The death-effector domain of FADD then recruits pro-caspase-8/10 to the receptor, 
resulting in the formation of death-inducing signaling complex (DISC). DISC activates 
effector caspases such as caspase-3 that in turn cleaves a restricted set of targets proteins 
and is responsible for apoptosis in the cell. [Houston A, et al. 2004] Our lab intended to 
combine NKG2D ligand, MULT1 and transmembrane and intracellular domains of Fas in 
an effort to create novel anti-cancer proteins. Both in vitro and in vivo results 
demonstrated that the protein is indeed bifunctional: activation of NK cells through 
NKG2D receptor and induction of apoptosis of tumor cells through FasTI.  [HSR K, et al. 
2008, 2010] 
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Based on the information discussed above, we intended to combine the NK cell-
mediated cytolysis and Fas- mediated apoptosis into one fusion protein by using mouse 
IL-12 and the transmembrane and intracellular domains of Fas in a mouse model. We 
hypothesized that the tumor cells expressing the fusion protein will not only send an 
apoptotic signal to tumor cells but also activate the NK cells through IL-12 receptor. 
Therefore, not only the engaged tumor cells will be killed via Fas-induced mechanisms, 
the neighboring tumor cells that do now express the protein will also be killed by 
activated NK cells.  
 
Materials and Methods 
Cells 
The mouse lung carcinoma TC-1 cells (ATCC No. CRL-2785) were cultured in RPMI 
1640 medium containing 10% fetal bovine serum and 100µg/ml gentamicin at 37℃ with 
5% CO2. 
Construction of pcDNA3.1 (+) mIL-12/FasTI/Zeo Vector 
Mouse IL-12 cDNA was cloned from pORF-mIL-12, and the 
transmembrane/intracellular domains of Fas was amplified from a previous pcDNA3.1 (+) 
MULT1E/FasTI/Zeo expression vector [Kotturi, et al., 2008] using 5’ primer 
(CGGGATCCCCCAGAAATCGCCTATGGTTGT TGACC) and 3’ primer 
(CGGAATTCTCACTCCAGACATTGTCCTTCATTTTC). To allow for the fusion of 
these two gene fragments, the mIL-12 stop codon was removed from the 3’ end of the 
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sequence during PCR amplification.  A (GGGS)3 linker sequence 
(GGTGGTGGTTCTGG TGGTGGTTCTGGTGGTGGTTCT) was added at the 3’ end of 
mIL-12 sequence to separate the two functional domains of fusion protein to maintain 
original folding and binding ability of the proteins [Argos 1990]. HindIII, BamHI, EcoRI 
restriction cutting sites were designed for 5’end of mIL-12, 3’/5’ ends of mIL-12 and 
FasTI and 3’end of FasTI, respectively. The primers are:  
5’IL-12: CCAAGCTTCCATGGGTC AATCACGCTACCTCC 
3’IL-12: 
CGCGGATCCAGAACCACCACCAGAACCACCACCAGAACCACCACCGGATCG 
GACCTGCAGGGAACACATGC 
5’FasTI: CGGGATCCCCCAGAAATCGCCTATGGTTGTTGACC 
3’FasTI: CGGAATTCTCACTCCAGACATTGTCCTTCATTTC 
 
The sequence of construct was confirmed using DNA sequencing. 
 
 
Construction of pDisplay (+) mIL-12 Vector  
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In order to create a cell membrane anchored form of moue IL-12, the IL-12 sequence was 
amplified from pORF-mIL-12 using 5’primer 
(CCCCCCGGGAGGGTCATTCCAGTCTCT) with XmaI restriction cutting site and a 3’ 
primer (TCCCCGCGGGGATCGGACCCTGCAG GGAAC) with a SacII restriction 
cutting site by PCR. The fragments were excised and gel purified using a gel purification 
kit (Qiagen, Valencia, CA, USA). Double enzyme digestion was performed on the 
purified fragments of mIL-12 and pDisplay vector (Invitrogen life technologies) using 
XmaI and SacII allowing for the insertion of mIL-12 into the vector. The enzyme 
digested mIL-12 fragment and pDisplay vector fragment were ligated to create the 
plasmid pDisplay (+) mIL-12. In order to make the expression vector zeocin resistant, 
restriction enzymes HindII and XhoI were used to cut plasmid pDisplay (+) mIL-12 and 
fragment containing mIL-12 sequence together with the cell membrane anchoring 
sequence was retrieved and inserted into plasmid pcDNA3.1/Zeo(+) to have plasmid 
pcDNA3.1(+)/mIL12/Zeo. 
The sequence was confirmed using DNA Sanger sequencing. 
Transfection of cells 
TC-1 cells were transfected with pcDNA3.1 (+) mIL-12/FasTI/Zeo or pcDNA3.1 (+) 
mIL-12/ Zeo using Lipofectamine 2000 (Invivogen) as directed by manufacturer. To 
obtain the stable clones expressing fusion protein or control protein, the transfected TC-1 
cells were cultured in selecting medium containing 200µg/ml zeocin. Drug-resistance 
clones were collected and sub-cultured in the presence of the selective drug. 
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RT-PCR 
Total RNA was extracted from each clone using an RNeasy Plus from Qiagen following 
the manufacturer’s directions. cDNAs were produced from 2µg of the total RNA using 
the QuantiTect RT kit from QIAgen following the manufacturer’s directions. Five 
microliters of the cDNA product were added to a PCR reaction containing primers 
amplifying a 1059 bp portion of mIL-12/FasTI fusion gene sequence containing 522bp of 
the mIL-12, the (GGGS)3’ linker sequence 
(GGTGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCT) , and the entire 495 bp of 
FasTI. A Phusion High-Fidelity DNA polymerase kit was used with a 5’ primer 
GCAGTGACATGTGGAATGGC and a 3’ primer CGGAATTCTCACTC 
CAGACATTGTCCTTCATTTTC. Similar reaction was also carried out to amplify 
portion of mIL-12 sequence using 5’ primer GGAAGCACGGCAGCAGAATA and 3’ 
primer AACTTGAGGGAGAAGT AGGAATGG to amplify a 180 bp fragment of mIL-
12. Beta-actin housekeeping gene was also amplified as controls. 
Immunohistochemistry (IHC) 
Glass slides having cells of Clones IL-12/8, IL12-Fas/10 and TC-1 were prepared using 
cytospin technology. 100,000 cells in 1 ml PBS were transferred into assembled cytospin 
cassettes and centrifuged in the CytoTek centrifuge at 2,000 rpm for 10 minutes at room 
temperature.  After centrifuge the cellson the slides were fixed with 4% para-
formaldehyde solution for 10 minutes. The cells were then stained using a cell staining 
kit (R& D Systems) following manufacturer’s directions. Rat IgG2a antibody was used as 
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isotype control (R&D Systems, clone #54447) and anti-mouse IL-12/p35 antibody was 
used for IL-12 staining (R&D Systems, clone #45806). Both primary antibodies were 
diluted as 1:500 by sterile PBS. Primary antibodies were incubated with the cells for an 
hour at room temperature. Secondary antibody conjugated with HSS-HRP was then 
incubated with the cells for 30 minutes at room temperature. DAB substrate-chromogen 
mixture was applied to the cells and incubated for 10 minutes. Slides were washed three 
times for 2 minutes using fresh PBS between steps. After the final incubation, the slides 
were rinsed with distilled water for 5 minutes, and then observed with a microscope 
(Olympus 1x70 fluorescent microscope). 
Proliferation assay 
To determine if the clones grow at the same rate as un-transfected TC-1 cells, cell 
proliferation was checked with the MTS assay every 24 hours for 5 days. On day one, 
4000 cells of each clone were plated on 12-well-plates in triplicates. At each time point, 3 
wells of each clone were tested with MTS.  The test was performed twice to obtain 6 
replicates. Clones were compared using a one-way ANOVA with Turkey’s post-test. 
Because there was no significant difference among the clones at any time point, the 
clones together with parental TC-1 cells were used in the following functional studies. 
NK cell activation 
 
Human NK92 cells and the cells of each clone at a ratio of 10:1 were plated on 96-well 
plate in 200 μl NK media and incubated for 48 hours. After incubation 100 μl of 
supernatant media was removed and analyzed for the presence of IFN-γ using BD 
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OptiEIA human IFN-γ ELISA kit II following manufacturer’s directions. The rest of the 
media as well as NK92 cells were removed.The proliferation of the remaining tumor cells 
was determined using Promega’s CellTiter 96ueous nonRadioactive cell proliferation 
assay following the manufacturer’s instructions. The data were analyzed using a one-way 
ANOVA with Turkey’s post-test. 
Apoptosis assay 
One million cells of each clone were first plated on a 6-well-plate and incubated for 24 
hours. At this point one million NK92 cells were added to the tumor cells and incubated 
for 2 hours. After removing NK cells, apoptosis of the tumor cells was determined by a 
caspase 3 assay kit (abcam) following the manufacturer’s instruction.  
 
Results 
Fusion gene construction 
(a) Plasmid pcDNA3.1 (+) mIL-12/FasTI/Zeo construction.  
Mouse IL-12 cDNA was cloned from pORF-mIL-12 using 5’ primer 
(CCAAGCTTCCATGGGTCAATCACGCTACCTCC) with HindIII cutting site and a 3’ 
primer 
(CGCGGATCCAGAACCACCACCAGAACCACCACCAGAACCACCACCGGATCG 
GACCTGCAGGGAACACATGC) with BamHI cutting site by PCR.  To allow for the 
fusion of these two cDNA fragments, the mIL-12 stop codon was removed from the 3’ 
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end of the sequence during PCR amplification.  A (GGGS) 3’ linker sequence 
(GGTGGTGGTT CTGGTGGTGGTTCTGGTGGT GGTTCT) was added at the 3’ end 
of mIL-12 sequence to separate the two functional domains of fusion protein to maintain 
original folding and binding ability of the proteins. The fragments were excised and gel 
purified using a gel purification kit. Double enzyme digestion was performed on the 
purified fragments of mIL-12 and pcDNA3.1/Zeo(+) vector using HindIII and BamHI 
allowing for the insertion of mIL-12 fragment into the vector. The enzyme digested mIL-
12 and pcDNA3.1/Zeo(+) vector fragments were ligated to create the plasmid 
pcDNA3.1/mIL-12(+). Then the transmembrane/intracellular domains of mouse Fas was 
cloned from a previous plasmid made in our lab: pcDNA3.1 (+) MULT1E/FasTI/Zeo 
using 5’ primer CGGGATCCCCCAGAAATCGCCTATGGTTGTTGACC and 3’ primer 
CGGAATTCTCACTCCAGACATTGTCCTTCATTTC. The fragments were excised 
and gel purified using a gel purification kit. Double enzyme digestion was performed on 
the purified fragments FasTI and pcDNA3.1/mIL-12(+) using BamHI and EcoRI for the 
insertion of FasTI into the plasmid. The enzyme digested FasTI and pcDNA3.1/mIL-12(+) 
fragments were  ligated to create the plasmid pcDNA3.1 (+) mIL-12/FasTI/Zeo. The 
resulting plasmid was confirmed by Restriction-enzyme double digest and DNA 
sequencing (CUGI).  (Figure 1.a) 
(b) Plasmid pcDNA3.1 (+) mIL-12/Zeo construction.  
The IL-12 sequence was amplified from pORF-mIL-12 using 5’primer 
(CCCCCCGGGAGGGTCATTCCAGTCTCT) with XmaI restriction cutting site and a 3’ 
- 41 - 
 
primer (TCCCCGCGGGGATCGGACCCTGCAG GGAAC) with a SacII restriction 
cutting site by PCR. The fragments were excised and gel purified using a gel purification 
kit. Double enzyme digestion was performed on the purified fragments of mIL-12 and 
pDisplay vector using XmaI and SacII allowing for the insertion of mIL-12 cDNA 
fragment into the vector. The enzyme digested mIL-12 fragment and pDisplay vector 
fragment were ligated to create the plasmid pDisplay (+) mIL-12. In order to make the 
expression vector zeocin resistant, restriction enzymes HindII and XhoI were used to cut 
plasmid pDisplay (+) mIL-12 and the fragment containing mIL-12 sequence together 
with the cell membrane anchoring sequence was retrieved and inserted into plasmid 
pcDNA3.1/Zeo(+) to have plasmid pcDNA3.1(+)/mIL12/Zeo.(Figure1.b)  
(a) 
(b) 
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Figure1. (a) Plasmid pcDNA3.1 (+) mIL-12/FasTI/Zeo. (b) Plasmid pcDNA3.1 (+) mIL-12/Zeo 
(containing PDGFR transmembrane domain)  
 
Stable clone establishment 
TC-1 lung carcinoma cells were transfected with pcDNA3.1 (+) mIL-12/FasTI/Zeo or 
pcDNA3.1 (+) mIL-12/ Zeo. Ten zeocin resistant clones were selected for each 
transfection, and the transgene expression was analyzed by RT-PCR. As shown in Figure 
2, all ten clones are positive for fusion protein IL12/FasTI and and cytokine IL12. Clones 
IL12/FasTI/3 (IF-3), IL12/FasTI/9(IF-9), IL12/FasTI/10 (IF-10) and IL12/8 were selected 
for protein expression studies using immunohistochemistry (IHC). IHC results 
demonstrated that clones of IF-9, IF-10 and IL12/8 expressed relatively high levels of IL-
12 on cell surface compared to control TC-1 cells, while fusion protein expression of of 
clone IF-3 was relatively low (Figure 3). 
NK cell activation 
It is critical to know whether fusion protein IL12/FasTI can effectively activate NK cells. 
Cells from TC-1 or clones of IF-9, IF-10 and IL12/8 were co-cultured with human NK92 
cells. After the co-culture, the INF-γ production in the supernatant was detected by 
human IFN-γ ELISA analysis and the cytotoxicity of tumor cells was analyzed using 
Promega’s CellTiter 96ueous nonRadioactive cell proliferation assay. The production of 
INF-γ was significantly increased by NK cells that co-cultured with  clone IF-9, IF-10 
and IL12/8 compared to those co-cultured with TC-1 parental cells (p<0.001, p<0.001 
43 
 
and p<0.05, respectively) (Figure 4). Fusion protein IL-12/FasTI significantly enhanced 
the cytotoxicity of NK cells (Figure 5). NK cells co-cultured with clone IF9 and IF10 
killed significantly more tumor cells (p<0.01, p<0.01) when compared with NK cells co-
cultured with control TC-1 cells. It is interesting to know that although NK cells co-
cultured with clone IL-12/8, which express only IL-12 on cell surface, killed significant 
tumor 
cells 
(p<0.05), the cytotoxicity is relatively lower than NK cells co-cultured with fusion 
protein expressing cells.  
  
1059 bp 
180 bp 
435 bp 
435 bp 
Figure 2. RT-PCR confirmation of gene expression in selected TC-1 clones. Total RNAs were isolated from the 
zeocin resistant clones and TC-1 cells and a two-step RT-PCR was performed using Phusion RT-PCR  kit (Thermo 
Scientific).(a) Detection of fusion gene MIL-12/FasTI expression; (b) detection of IL-12 expression. House-keeping 
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Figure 3. Fusion gene expression at protein level by Immunohistochemistry (IHC). Cells from clones and TC-1 cells 
were harvested and cytospun onto class slides. After fixation, the cells were stained with anti-mouse IL-12 antibody 
or isotype control antibody followed by anti-mouse IgG secondary antibody conjugated with HRP. The cells were 
then treated with substrate DAB and observed under microscope.   
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Figure 4. IFN-γ production by human NK92 cells. Cells of clones and TC-1 in triplicates were co-cultured with 
human NK 92 cells for NK cell activation and the supernatants were collected. IFN-γ activity in the supernatants was 
detected using Human IFN- γ ELISA Kit. The statistical analyses were conducted between the controls (NK+TC1) 
and IL-12 expressing control and IL12-FasTI expressing clones using one-way analysis of variance (ANOVA) with 
Tukey’s post test. (*p<0.05; ***p<0.001) 
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because NK cells were activated through IL-12/IL-12R pathway. This difference in IFN-γ  
production might be due to different transfection levels.  Although the killing by NK cells 
activated by clone IL-12/8 (p<0.01) is not statistically significant compared to NK cells 
activated by clone IL9 or IL10 (p<0.001), it shows the trends. (Figure 5). 
Fusion protein IL12/FasTI induces apoptosis of tumor cells 
To confirm the hypothesis that when bound to IL-12 receptor, fusion protein IL-12/FasTI 
can also send death signals through its FasTI portion into the tumor cells, TC-1 cells and 
clones IF-10 and IL12/8 were co-cultured with NK cells to induce apoptosis. Caspase 3 
assay was performed to analyze the apoptosis in tumor cells (Figure 6). After co-culture, 
the caspase 3 activities of clone IF9 and IF10 were much higher than un-induced controls 
(p<0.01 and p<0.001, respectively), while TC-1 and clone IL12/8 showed no significant 
difference after treatment.   
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Figure 5. Cytotoxicity of NK cells. Cells of clones and TC-1 in triplicates were co-cultured with human NK 92 cells for NK cell 
activation. After co-culture, NK cells were removed and remaining tumor cells’ proliferation was measured with Promega’s 
CellTiter 96ueous nonRadioactive cell proliferation assay kit. The statistical analyses were conducted between the controls 
(NK+TC1) and IL-12 expressing control and IL12-FasTI expressing clones using one-way analysis of variance (ANOVA) with 
the Tukey’s post test (**p<0.01, ***p<0.001) 
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Figure 6. Induction of apoptosis in tumor cells. A total of 1x106 cells of TC-1 and clones IF9, IF10 and IL-
12/8 in triplicates were co-cultured with NK 92 cells for 2 hours. After the removal of NK cells, the caspase 
3 activities in the remaining tumor cells were detected using a Caspase 3 Assay Kit (abcam). The statistical 
analyses were conducted between the corresponding un-induced and induced groups using one-way 
analysis of variance (ANOVA) with the Tukey’s post test (**p<0.01, ***p<0.001) 
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Discussion 
 
Different strategies using NK cells for anti-tumor immunotherapy such as in vivo 
cytokine therapy to expand and activate NK cells against tumor cells have been used 
[Law TM et al.1995; Meropol NJ et al. 1998]. However, a majority of these studies failed 
to demonstrate significant clinical benefit. As tumors have developed multiple 
mechanisms to subvert and suppress immune responses by deregulating cell surface 
expression of Fas and Fas ligand resulting in reduced sensitivity of tumor cells to Fas-
mediated apoptosis. This resistance to Fas-mediated apoptosis protects tumor cells from 
killing by infiltrating antitumor NK cells and T cells [Elsasser-Beile U et al. 2003]. NK 
cells require activating receptors as well as activating cytokine, like IL-12, to function. 
The systemic infusion of IL-12 in high amounts is effective in activating an immune 
response against tumor cells but it is toxic to most patients. In this study, we introduced 
mouse IL-12, one of most important and potent NK cell activating cytokine, and the DD 
of Fas in the transmembrane and intracellular domain into one fusion protein IL12/FasTI. 
It is hypothesized that the development of this bi-functional chimeric protein can send an 
apoptosis signal to the tumor cells and at the same time activate NK cells and other 
immune cells.  
The transcription of fusion protein in zeocin resistant clones isolated from 
transfected TC-1 cells was confirmed by RT-PCR and the expression of the fusion 
protein was further characterized by cell surface immunohistochemistry (IHC). In the 
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RT-PCR experiment, a pair of primers were designed to cover the entire IL-12 fragment 
and partial upstream fragment of FasTI; thus only clones expressing fusion protein 
showed positive (Figure 2). In the IHC analysis, when anti-mouse IL12 antibody was 
used, clone IF-3, IF-9, IF-10 and IL-12/8 showed positive, whereas TC-1 cells were 
negative (Figure 3). However, the expression level of IF-10 and IL-12/8 was significantly 
higher. The IHC analysis matched with RT-PCR result. 
Increased production of IFN-γ is a key indicator of NK cell activation [Bryceson 
YT et al. 2006]. To confirm the idea that fusion protein IL12/FasTI activates immune 
cells that express IL-12R, human NK92 cells were co-incubated with cells of TC-1 and 
clones IF-9, IF-10 and IL-12/8 and IFN-γ expression was detected by human IFN-γ 
ELISA. The IFN-γ expression by NK cells co-cultured with cells of clones IF-9, IF-10 
and IL-12/8 significantly increased compared to those of NK cells co-cultured with cells 
of TC-1 (Figure 4). Our result also indicated NK cells alone are capable of producing 
high level of IFN-γ..It is hypothesized that, when co-cultured with TC-1 cells, tumor cells 
expressing ligands for NK inhibitory receptors inhibited NK cell cytotoxicity. Our ELISA 
result demonstrated that fusion protein clones significantly enhanced NK cell function 
compared to TC-1 clones in the tumor environment.  More importantly, the cytotoxicity 
assay further demonstrated that fusion protein clones IF-9 and IF-10 were more effective 
in inducing NK mediated cell killing than IL-12/8 clone expressing membrane anchored 
IL-12. Compared to IL-12/8 clone, our fusion protein clones were capable of both 
activating NK cell cytotoxicity and inducing  Fas-mediated apoptosis, thus exerting bi-
functional killing of tumor cells effectively(Figure 5). 
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Another key feature of the designed fusion protein is to send apoptosis signals into the 
cells expressing the protein after binding to its ligand. Although we do not have direct 
evidence supporting that the binding of IL-12 to IL-12R on NK cells can trigger FasTI to 
form DISC inside tumor cells, a clear apoptosis signal is send to targeted tumor cells as 
indicated by the increased caspase-3 activity after co-culture of the clones with NK cells. 
(Figure 6). This also agrees with the results of cytotoxicity study (Figure 5). It is 
interesting to note that when NK cells and fusion protein expressing clones were co-
cultured longer than 4 hours, most of tumor cells died, very likely due to induced 
apoptosis. (data not shown) Therefore, the apoptotic assay was finalized with two-hour 
co-culture of NK cells and clones.  
In conclusion, a bi-functional chimeric protein containing the extracellular 
domain of mouse IL-12 and transmembrane and intracellular domains of Fas is created. 
In vitro studies demonstrate that the fusion protein can activate NK cells for anti-tumor 
cytotoxicity and induce apoptosis in tumor cells. In the future, engineered nanoparticles 
or lentivirus will be tested for fusion protein delivery in vitro. Hopefully, tumor cells can 
be precisely targeted and eliminated using fusion protein together with potential delivery 
system. 
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